Show Summary Details
Page of

Management of Mucosal and Ocular Melanoma 

Management of Mucosal and Ocular Melanoma
Management of Mucosal and Ocular Melanoma

Alexander N. Shoushtari

and Richard D. Carvajal

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 02 July 2020

Malignant melanomas account for 1–2% of all malignancies, with the vast majority of cases representing cutaneous primary tumors. In 5–10% of cases, however, melanoma arises from mucosal areas, the uveal tract of the eye, or an unknown primary site. Recently, advances in targeted kinase inhibitors and immune therapy have revolutionized the treatment of melanoma. These trials were largely conducted in cutaneous melanoma, however, and there are fewer published data regarding therapy in mucosal and ocular melanomas. Given the increasing knowledge of the distinct molecular changes underlying these various melanoma subtypes, it is increasingly important to understand the distinct epidemiology, presentation, prognosis, and treatment options for these subtypes.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.